Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction

Thrombosis and Haemostasis

Volumn 87, Issue 2, 2002, Pages 311-316

  Boman, Kurt O A ^a   Jansson, Jan Håkan ^a   Nyhlén, Katarina A ^a   Nilsson, Torbjörn K ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

ACE inhibitor; Fibrinolysis; Myocardial infarction; Plasminogen activator inhibitor; Tissue plasminogen activator

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIGITALIS; DIURETIC AGENT; ENALAPRIL; FIBRINOLYTIC FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM SPARING DIURETIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL;

EID: 0036166694     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612991     Document Type: Article

References (40)

1. On the usefulness of fibrinolytic variables in the characterisation of a risk group for myocardial infarction
2. The hemostatic system and coronary heart disease
3. A depression of active tissue plasminogen activator in plasma characterises patients with unstable angina pectoris who develop myocardial infarction
4. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris
5. Impaired fibrinolysis and the risk for coronary heart disease
6. High plasminogen activator inhibitor (PAI-1) and tissue plasminogen activator (tPA) levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
7. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
8. Prospective study of hemostatic factors and incidence of coronary heart disease. The ARIC Study
9. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
10. Stimulation of plasminogen activator in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
11. Effect of enalapril on mortality in severe congestive heart failure: Result of the Cooperative North Scandinavian Enalapril Survival Study
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
13. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
14. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction
15. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
16. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
17. Effects of captopril on fibrinolytic function in healthy humans
18. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction?
19. Fibrinolytic variables are related to age, sex, blood pressure and body build measurements: A cross-sectional study in Norsjö, Sweden
20. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study
21. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
22. Diurnal variation of the fibrinolytic system
23. An enzyme-linked immunosorbent assay for tissue plasminogen activator applied to patients with thromboembolic disease
24. Enzyme immunoassay for factor VIII-related antigen
25. Determination of tissue plasminogen activator and its "fast" inhibitor from plasma
26. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma
27. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
28. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
29. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
30. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: A cross-sectional study in Norsjö, Sweden
31. Predictive value of tissue plasminogen activator massconcentration on long-term mortality in patients with angiographically verified coronary heart disease: A 7-year follow-up
32. Von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome
33. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial
34. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B82 receptor-dependent, NO synthetase-independent, and cyclooxygenase-independent pathway
35. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man
36. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: Effects of angiotensin-converting enzyme inhibitors
37. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human monocytes
38. Angiotensin-converting enzyme inhibitor suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta
39. Role of superoxide in angiotensin II-induced but not catecholamine induced hypertension
40. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts